Search Results 171-180 of 16436 for monoclonal antibody

  1. Publications - Melissa R. Snyder, Ph.D. - Mayo Clinic

    Lack of observed interference by therapeutic monoclonal antibodies ... Monoclonal antibody therapeutics as potential interferences on protein electrophoresis and ...

  2. Melphalan flufenamide (intravenous route) - Mayo Clinic

    ... monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent) that did not work well. Melphalan flufenamide belongs to the group of medicines ...

  3. Mayo Clinic Model of Care and Research leads to favorable outcomes for patients with COVID-19

    ... monoclonal antibody or convalescent plasma. Nearly one-quarter of hospitalized patients received two therapies, most commonly a combination of steroids and ...

  4. Colon Melanoma Clinical Trials

    Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find ...

  5. Health Topics - Mayo Clinic News Network

    Monoclonal antibody treatment helps couple recover quickly from COVID-19. Dan Lea. February 23, 2021. COVID-19. Changes for visitors at Mayo Clinic in Rochester.

  6. Mayo Clinic expert provides perspective on FDA approval of another experimental Alzheimer's drug

    A monoclonal antibody, lecanemab, shows promise in removing amyloid plaques from the brain, according to phase 3 trial results. Amyloid plaques are one of ...

  7. Blistering (Bullous) Diseases Clinical Trials - Mayo Clinic Research

    Ixekizumab is a recombinant high-affinity fully human monoclonal antibody that targets IL-17A Immunoglobulin gamma-1 (IgG1)/kappa-class. The purpose of this ...

  8. Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas - Mayo Clinic

    Monoclonal antibodies can block cancer growth in different ways. ... Prior anti-cancer monoclonal antibody < 28 days prior to registration or who ...

  9. A Study of the Effectiveness and Safety of Mepolizumab as Adjunctive Therapy in Participants with Severe Eosinophilic Asthma - Mayo Clinic

    Participants who have received any monoclonal antibody (other than Xolair) to treat inflammatory disease within 5 half-lives of visit 1; Participants who ...

  10. Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients with Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma - Mayo Clinic

    RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, can ...